FDA Approves Epclusa for Chronic Hepatitis C

Share this content:
FDA Approves Epclusa for Chronic Hepatitis C
FDA Approves Epclusa for Chronic Hepatitis C

TUESDAY, June 28, 2016 (HealthDay News) -- The combination drug Epclusa has been approved by the U.S. Food and Drug Administration to treat the six major strains of chronic hepatitis C virus.

Epclusa combines sofosbuvir, FDA-approved in 2013, and the new drug velpatasvir. For patients with moderate-to-severe cirrhosis, Epclusa is approved to be used in combination with ribavirin. Epclusa also is approved for use in patients who haven't developed cirrhosis, the agency said Tuesday in a news release.

Epclusa was evaluated in clinical trials involving 1,558 patients. Up to 99 percent of participants given the drug had no virus detected in the blood 12 weeks after treatment, the FDA said. The most common side effects reported were headache and fatigue. The drug's label warns that Epclusa, when used with certain other drugs, including amiodarone, could lead to symptomatic bradycardia.

"This approval offers a management and treatment option for a wider scope of patients with chronic hepatitis C," Edward Cox, M.D., director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research, said in a statement.

Epclusa is produced and marketed by Gilead Sciences, based in Foster City, Calif.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Progress Made on Genetic Test for Anal Cancer

Progress Made on Genetic Test for Anal Cancer

But research is still in early stages

Four Separate Events Led to Zika's Introduction Into Florida

Four Separate Events Led to Zika's Introduction Into ...

Virus strains came from the Caribbean and Latin America, researchers say

New Health Care Act Could Result in 23 Million Losing Insurance

New Health Care Act Could Result in 23 ...

While premiums may lower over the long-term, many would face much higher out-of-pocket costs

is free, fast, and customized just for you!

Already a member?

Sign In Now »